Visen Pharmaceuticals Announces First Time Detailed Clinical Data From Phase 3 Trial Of Lonapegsomatropin
Visen Pharmaceuticals, An Innovative Biopharmaceutical Company Focused On Endocrine Diseases, Has Announced For The First Time Detailed Clinical Data From Its Pivotal Phase 3 Study Of Lonapegsomatropin, A Long-Acting Prodrug Of Unmodified Somatropin Being Investigated As A Once-Weekly Injection In Children With Growth Hormone Deficiency (Ghd) In China.The Data Showed That Lonapegsomatropin Demonstrated An Annualized Height Velocity (Ahv) Of 10.66 Cm/Year Compared To 9.75 Cm/Year For The Daily Hgh At 52 Weeks (Treatment Difference At 0.91 Cm/Year With A 95 Per Cent Confidence Interval: 0.37
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!